We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Enavail Applies Particle Engineering Technologies to Increase Drug Solubility, Stability and Bioavailability

News   Nov 11, 2009

 
Enavail Applies Particle Engineering Technologies to Increase Drug Solubility, Stability and Bioavailability
 
 
Advertisement
 

RELATED ARTICLES

Olaparib Successfully Treats Prostate Cancers With Genetic Fault in Clinical Trial

News

Results from the PROfound trial have showed that olaparib – a drug called a PARP inhibitor – can be used successfully to treat prostate cancers with a "weakness" in their ability to repair damaged DNA.

READ MORE

Phase 3 Clinical Trial of Belimumab for Lupus Nephritis Reports Positive Results

News

Results from the largest Phase 3 lupus nephritis clinical trial ever conducted were announced, September 16. The study, found positive results of the efficacy and safety of the drug belimumab in patients with active lupus nephritis, a condition that causes inflammation in the kidneys of patients with systemic lupus erythematosus.

READ MORE

Shining Light on Photoconversion in Green Fluorescent Protein

News

Scientists from the Skolkovo Institute of Science and Technology (Skoltech), the Institute of Bioorganic Chemistry (IBCh RAS) and Lomonosov Moscow State University (MSU) undertook a detailed study on green-to-red photoconversion (light-induced conversion) of the Green Fluorescent Protein (GFP).

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE